Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026)
Maze Therapeutics (MAZE) posted Operating Expenses of $46.6 million for Q1 2026, up 22.32% sequentially from $38.1 million in Q4 2025, and up 31.5% YoY from $35.4 million in Q1 2025.
Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Operating Expenses for 3 years, with the latest figure at $46.6 million in Q1 2026.
- Quarterly Operating Expenses rose 31.5% year-over-year to $46.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.1 million (up 31.33% YoY) and the FY2025 annual result came in at $142.9 million, up 30.01% from the prior year.
- Operating Expenses climbed to $46.6 million in Q1 2026 per MAZE's latest filing, from $38.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $46.6 million in Q1 2026 and troughed at $25.4 million in Q2 2024.
- A 3-year average of $33.3 million and a median of $33.0 million in 2025 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 43.34% in 2025, down 23.33% in 2025.
- Over 3 years, Operating Expenses stood at $29.7 million in 2024, then rose by 28.03% to $38.1 million in 2025, then increased by 22.32% to $46.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $46.6 million, $38.1 million, and $33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 48.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.04 Mn |
| Mar 31, 2026 | 46.55 Mn |
| Dec 31, 2025 | 38.06 Mn |
| Sep 30, 2025 | 32.97 Mn |
| Jun 30, 2025 | 36.47 Mn |
| Mar 31, 2025 | 35.40 Mn |
| Dec 31, 2024 | 29.73 Mn |
| Sep 30, 2024 | 26.73 Mn |
| Jun 30, 2024 | 25.45 Mn |
| Mar 31, 2024 | 28.01 Mn |